PHARMATHER HOLDINGS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.25 CAD | +4.17% |
|
+11.11% | -20.63% |
Valuation
| Fiscal Period: May | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 19.53 | 13.13 | 9.699 |
| Enterprise Value (EV) 1 | 13.65 | 1.007 | 3.445 |
| P/E ratio | 7 x | -3 x | -1.51 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -5,616,845 x | -254,234 x | -870,412 x |
| EV / FCF | -13,533,150 x | -523,177 x | -1,787,976 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 3.4 x | 1.12 x | 1.79 x |
| Nbr of stocks (in thousands) | 69,735 | 87,522 | 88,169 |
| Reference price 2 | 0.2800 | 0.1500 | 0.1100 |
| Announcement Date | 9/7/21 | 9/28/22 | 9/28/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA | - | -2.43 | -3.96 | -3.958 |
| EBIT 1 | -0.1429 | -2.43 | -3.962 | -3.96 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.1429 | 2.889 | -4.236 | -6.416 |
| Net income 1 | -0.1429 | 2.664 | -4.011 | -6.416 |
| Net margin | - | - | - | - |
| EPS | - | 0.0400 | -0.0500 | -0.0728 |
| Free Cash Flow | - | -1.008 | -1.924 | -1.927 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 7/22/20 | 9/7/21 | 9/28/22 | 9/28/23 |
1CAD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: May | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | -1.037 | -1.087 | -1.463 | -1.221 | -0.8303 |
| EBIT 1 | -1.037 | -1.087 | -1.464 | -1.222 | -0.8307 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 1/27/22 | 4/25/22 | 9/28/22 | 10/26/22 | 1/26/23 |
1CAD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 0.39 | 5.88 | 12.1 | 6.25 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -1.01 | -1.92 | -1.93 |
| ROE (net income / shareholders' equity) | - | 89.4% | -46.1% | -74.4% |
| ROA (Net income/ Total Assets) | - | -48% | -27.3% | -26.8% |
| Assets 1 | - | -5.556 | 14.67 | 23.95 |
| Book Value Per Share 2 | 0.0100 | 0.0800 | 0.1300 | 0.0600 |
| Cash Flow per Share 2 | 0.0100 | 0.0400 | 0.1000 | 0.0700 |
| Capex | - | 0 | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 7/22/20 | 9/7/21 | 9/28/22 | 9/28/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.63% | 15.52M | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
- Stock Market
- Equities
- PHRM Stock
- Financials PharmaTher Holdings Ltd.
